Prelude Therapeutics Incorporated (PRLD) Tops Q3 EPS by 4c

Prelude Therapeutics Incorporated (NASDAQ: PRLD) reported Q3 EPS of ($0.43), $0.04 better than the analyst estimate of ($0.47). Revenue for the quarter came in at $3 million versus the consensus estimate of $0 .

For earnings history and earnings-related data on Prelude Therapeutics Incorporated (PRLD) click here.

You May Also Be Interested In

• Keefe, Bruyette & Woods Downgrades Bain Capital Specialty Finance (BCSF) to Market Perform
• Defence Therapeutics names Ryan Simms as COO and radiopharmaceutical head
• HSBC Upgrades YPF S.A. (YPF) to Buy